Daily Archives: May 1, 2020

COVID-19: What’s RNA research got to do with it? – University of Rochester

Posted: May 1, 2020 at 3:52 pm

April 28, 2020

Rochester research into RNA structure and function provides key information for developing coronavirus treatments.

Viruses like the coronavirus that causes COVID-19 are able to unleash their fury because of a devious weapon: ribonucleic acid, also known as RNA.

A contingent of researchers at the University of Rochester study the RNA of viruses to better understand how RNAs work and how they are involved in diseases. As COVID-19 continues to spread around the globe, RNA research provides an important foundation for developing antiviral drugs, vaccines, and other therapeutics to disrupt the virus and stop infections.

The Universitys website is a way to find guidance and critical information during a rapidly changing situation.

Find out what to do if you or a close contact have symptoms or think you may have been exposed.

Understanding RNA structure and function helps us understand how to throw a therapeutic wrench into what the COVID-19 RNA doesmake new virus that can infect more of our cells and also the cells of other human beings, says Lynne Maquat, professor of biochemistry and biophysics at the University of Rochester Medical Center and the director of Rochesters Center for RNA Biology.

In the past few decades, as scientists came to realize that genetic material is largely regulated by the RNA it encodes, that most of our DNA produces RNA, and that RNA is not only a target but also a tool for disease therapies, the RNA research world has exploded, Maquat says. The University of Rochester understood this.

In 2007, Maquat founded the Center for RNA Biology as a means of conducting interdisciplinary research in the function, structure, and processing of RNAs. The center involves researchers from both the River Campus and the Medical Center, combining expertise in biology, chemistry, engineering, neurology, and pharmacology.

While much of the research across the University has been put on pause, labs that are involved in coronavirus research remain active.

Our strength as a university is our diversity of research expertise, combined with our highly collaborative nature, says Dragony Fu, an assistant professor of biology on the River Campus and a member of the Center for RNA Biology. We are surrounded by outstanding researchers who enhance our understanding of RNA biology, and a medical center that provides a translational aspect where the knowledge gained from RNA biology can be applied for therapeutics.

In mammals, such as humans, DNA contains genetic instructions that are transcribedor copiedinto RNA. While DNA remains in the cells nucleus, RNA carries the copies of genetic information to the rest of the cell by way of various combinations of amino acids, which it delivers to ribosomes. The ribosomes link the amino acids together to form proteins that then carry out functions within the human body.

Many diseases occur when these gene expressions go awry.

COVID-19, short for coronavirus disease 2019, is caused by the novel coronavirus SARS-CoV-2. Like many other viruses, SARS-CoV-2 is an RNA virus. This means that, unlike in humans and other mammals, the genetic material for SARS-CoV-2 is encoded in RNA. The viral RNA is sneaky: its features cause the protein synthesis machinery of our cells to mistake it for RNA produced by our own DNA.

While SARS-CoV-2 is a new coronavirus, it likely replicates and functions similar to related coronaviruses that infect animals and humans, says Douglas Anderson, an assistant professor of medicine in the Aab Cardiovascular Research Institute and a member of the Center for RNA Biology, who studies how RNA mutations can give rise to human disease.

A graphic created by the New York Times illustrates how the coronavirus that causes COVID-19 enters the body through the nose, mouth, or eyes and attaches to our cells. Once the virus is inside our cells, it releases its RNA. Our hijacked cells serve as virus factories, reading the viruss RNA and making long viral proteins to compromise the immune system. The virus assembles new copies of itself and spreads to more parts of the body andby way of saliva, sweat, and other bodily fluidsto other humans.

Once the virus is in our cells, the entire process of infection and re-infection depends on the viral RNA, Maquat says.

Researchers Douglas Anderson, Dragony Fu, and Lynne Maquat are among the scientists at the University of Rochester who study the RNA of viruses to better understand how RNAs work and how they are involved in diseases. (University of Rochester photos / Matt Wittmeyer / J. Adam Fenster)

Maquat has been studying RNA since 1972 and was part of the earliest wave of scientists to realize the important role RNA plays in human health and disease.

Our cells have a number of ways to combat viruses in what can be viewed as an arms race between host and virus. One of the weapons in our cells arsenal is an RNA surveillance mechanism Maquat discovered called nonsense-mediated mRNA decay (NMD).

Nonsense-mediated mRNA decay protects us from many genetic mutations that could cause disease if NMD was not active to destroy the RNA harboring the mutation, she says.

Maquats discovery has contributed to the development of drug therapies for genetic disorders such as cystic fibrosis, and may be useful in developing treatments for coronavirus.

NMD also helps us combat viral infections, which is why many viruses either inhibit or evade NMD, she adds. The genome of the virus COVID-19 is a positive-sense, single-stranded RNA. It is well known that other positive-sense, single-stranded RNA viruses evade NMD by having RNA structures that prevent NMD from degrading viral RNAs.

Maquats lab is currently collaborating with a lab at Harvard University to test how viral proteins can inhibit the NMD machinery.

Like Maquat, Fu studies fundamental aspects of RNAand has found that his research on proteins may, too, be applicable to coronavirus research.

Fus lab analyzes enzymes and proteins that modify the chemical structure of RNA and how these chemical modifications impact the function of RNA. A research group at the University of California, San Francisco, recently identified an interaction between a protein made by the SARS-CoV-9 virus and a protein Fu studies.

This is an intriguing result, and we are currently thinking of ways this interaction could affect the host cell, Fu says. There is emerging evidence that RNA-based viruses undergo RNA modification, so we could use this knowledge to identify key links between the host and pathogen for development of a coronavirus vaccine or treatment.

One of the reasons viruses are such a challenge is that they change and mutate in response to drugs.

Targeting viral RNA, or the proteins it produces, is key for treating this disease.

That means novel virus treatments and vaccines have to be created each time a new strain of virus presents itself. Armed with innovative research on the fundamentals of RNA, scientists are better able to develop and test therapeutics that directly target the RNAs and processes critical to a viruss life cycle.

The University of Rochester Medical Center, for instance, is currently participating in a clinical trial to evaluate the safety and efficacy of a potential coronavirus treatment called remdesivir, an antiviral drug particularly tailored to attack RNA viruses. The drug inhibits RNA polymerase, an enzyme responsible for copying a DNA sequence into an RNA sequence.

Anderson has found that alternative therapeutics, such as the gene-editing technology CRISPR, may additionally usher in a new approach to how we target and combat infectious diseases, he says.

For the past few years, Andersons lab has developed tools and delivery systems that use the RNA-targeting CRISPR-Cas13 to treat human genetic diseases that affect muscle function. CRISPR-Cas13 is like a molecular pair of scissors that can target specific RNAs for degradation, using small, programmable guide RNAs.

When the health crisis first became apparent in Wuhan, China, researchers in Andersons lab turned their focus toward developing a CRISPR-Cas13 therapeutic aimed at SARS-CoV-2. Applying the knowledge already available about coronavirus RNA replication, they designed single CRISPR guide RNAs capable of targeting every viral RNA that is made within a SARS-CoV-2 infected cell. Using a novel cloning method developed in Andersons lab, multiple CRISPR guide-RNAs could be packaged into a single therapeutic vector (a genetically engineered carrier) to target numerous viral RNA sites simultaneously. The multi-pronged targeting strategy could be used as a therapy to safeguard against virus-induced cell toxicity and prevent escape of viruses which may have undergone mutation.

Infectious viruses and pandemics seemingly come out of nowhere, which has made it hard to rapidly develop and screen traditional small molecule therapeutics or vaccines, Anderson says. There is a clear need to develop alternative targeted therapeutics, such as CRISPR-Cas13, which have the ability to be rapidly reprogrammed to target new emerging pandemics.

While many new treatments for the novel coronavirus are being considered, there is one thing that is certain, Maquat says: Targeting viral RNA, or the proteins it produces, is key for treating this disease.

Tags: Arts and Sciences, Center for RNA Biology, COVID-19, Department of Biochemistry and Biophysics, Department of Biology, Douglas Anderson, Dragony Fu, featured-post, Lynne Maquat, medical center

Category: Featured

Here is the original post:
COVID-19: What's RNA research got to do with it? - University of Rochester

Posted in Gene Medicine | Comments Off on COVID-19: What’s RNA research got to do with it? – University of Rochester

New Data For Teva AJOVY (fremanezumab-vfrm) Injection and AUSTEDO (deutetrabenazine) Tablets Included in Neurology – BioSpace

Posted: at 3:52 pm

TEL AVIV & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data for AJOVY (fremanezumab-vfrm) injection and AUSTEDO (deutetrabenazine) tablets have appeared in an online supplement to Neurology. The data includes 23 abstracts that highlight a diverse set of data evaluating the efficacy and safety of AJOVY and AUSTEDO.

The abstracts were originally planned for presentation at the recently cancelled 2020 American Academy of Neurology (AAN) annual meeting. In addition to the online supplement, the abstracts are also available through the AAN online abstracts website.

We are pleased to have an opportunity to share this important data with the neurology community which build upon our understanding of the efficacy and safety of AJOVY and AUSTEDO across various patient populations, and further demonstrate Tevas commitment to the CNS space, said Denisa Hurtukova, MD, VP, Head of North America Medical Affairs. Teva is committed to ongoing evaluation of these significant therapies to help physicians, healthcare providers and most importantly, patients, make informed decisions about their treatments.

The featured abstracts include new AJOVY and AUSTEDO data, including results from an open-label extension of the FOCUS study, a Phase IIIb study that evaluated the efficacy and safety of quarterly and monthly treatment with AJOVY compared to placebo in adult patients with migraine and documented inadequate response to 2-4 classes of prior preventive treatments. Another analysis using the FDA Adverse Events Reporting System (FAERS) provides patient and healthcare professional insight into the real-world experience with CGRP pathway-targeted therapies. In addition, new data is available from a long-term, open-label extension study which examined the safety of AUSTEDO at higher doses beyond the approved maximum dose to treat chorea associated with Huntingtons disease, as well as the long-term experience with AUSTEDO in both younger and older patients with tardive dyskinesia.

The full list of Teva abstracts in the Neurology supplement includes:

AUSTEDO (deutetrabenazine) Tablets:

De Novo:

Encore:

AJOVY (fremanezumab-vfrm) Injection:

De Novo:

Encore:

About AJOVY (fremanezumab-vfrm) injection

AJOVY is available as a 225 mg/1.5 mL single dose injection in a prefilled syringe with two dosing options 225 mg monthly administered as one subcutaneous injection, or 675 mg every three months (quarterly), which is administered as three subcutaneous injections. AJOVY can be administered in office by a healthcare professional or at home by a patient or caregiver. No starting dose is required to begin treatment. The AJOVY autoinjector has been approved by the FDA and is available in the U.S. In addition to the U.S., the AJOVY autoinjector is currently available in Germany and should soon be available in other select European markets.

U.S. Important Safety Information about AJOVY (fremanezumab-vfrm) injection

Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.

Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.

Adverse Reactions: The most common adverse reactions (5% and greater than placebo) were injection site reactions.

Please click here for full U.S. Prescribing Information for AJOVY (fremanezumab-vfrm) injection.

About AUSTEDO (deutetrabenazine)

AUSTEDO is a vesicular monoamine transporter 2 (VMAT2) inhibitor approved by the U.S. Food and Drug Administration for the treatment of tardive dyskinesia in adults and for the treatment of chorea associated with Huntingtons disease. Safety and effectiveness in pediatric patients have not been established.

AUSTEDO Indications and Usage

AUSTEDO is indicated for the treatment of chorea associated with Huntingtons disease and for the treatment of tardive dyskinesia in adults.

Important Safety Information About AUSTEDO

Depression and Suicidality in Patients with Huntingtons Disease: AUSTEDO can increase the risk of depression and suicidal thoughts and behavior (suicidality) in patients with Huntingtons disease. Balance the risks of depression and suicidality with the clinical need for treatment of chorea. Closely monitor patients for the emergence or worsening of depression, suicidality, or unusual changes in behavior. Inform patients, their caregivers, and families of the risk of depression and suicidality and instruct them to report behaviors of concern promptly to the treating physician. Exercise caution when treating patients with a history of depression or prior suicide attempts or ideation. AUSTEDO is contraindicated in patients who are suicidal, and in patients with untreated or inadequately treated depression.

Contraindications: AUSTEDO is contraindicated in patients with Huntingtons disease who are suicidal, or have untreated or inadequately treated depression. AUSTEDO is also contraindicated in: patients with hepatic impairment; patients taking reserpine or within 20 days of discontinuing reserpine; patients taking monoamine oxidase inhibitors (MAOIs), or within 14 days of discontinuing MAOI therapy; and patients taking tetrabenazine (Xenazine) or valbenazine (Ingrezza).

Clinical Worsening and Adverse Events in Patients with Huntingtons Disease: AUSTEDO may cause a worsening in mood, cognition, rigidity, and functional capacity. Prescribers should periodically re-evaluate the need for AUSTEDO in their patients by assessing the effect on chorea and possible adverse effects.

QTc Prolongation: Tetrabenazine, a closely related VMAT2 inhibitor, causes an increase in the corrected QT (QTc) interval. A clinically relevant QT prolongation may occur in some patients treated with AUSTEDO who are CYP2D6 poor metabolizers or are co-administered a strong CYP2D6 inhibitor. Dose reduction may be necessary. The use of AUSTEDO in combination with other drugs known to prolong QTc may result in clinically significant QT prolongations. For patients requiring AUSTEDO doses greater than 24 mg per day who are using AUSTEDO with other drugs known to prolong QTc, assess the QTc interval before and after increasing the dose of AUSTEDO or the other drugs. AUSTEDO should be avoided in patients with congenital long QT syndrome and in patients with a history of cardiac arrhythmias.

Neuroleptic Malignant Syndrome (NMS), a potentially fatal symptom complex reported in association with drugs that reduce dopaminergic transmission, has been observed in patients receiving tetrabenazine. The risk may be increased by concomitant use of dopamine antagonists or antipsychotics. The management of NMS should include immediate discontinuation of AUSTEDO; intensive symptomatic treatment and medical monitoring; and treatment of any concomitant serious medical problems.

Akathisia, Agitation, and Restlessness: AUSTEDO may increase the risk of akathisia, agitation, and restlessness. The risk of akathisia may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops akathisia, the AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

Parkinsonism: AUSTEDO may cause parkinsonism in patients with Huntingtons disease or tardive dyskinesia. Parkinsonism has also been observed with other VMAT2 inhibitors. The risk of parkinsonism may be increased by concomitant use of dopamine antagonists or antipsychotics. If a patient develops parkinsonism, the AUSTEDO dose should be reduced; some patients may require discontinuation of therapy.

Sedation and Somnolence: Sedation is a common dose-limiting adverse reaction of AUSTEDO. Patients should not perform activities requiring mental alertness, such as operating a motor vehicle or hazardous machinery, until they are on a maintenance dose of AUSTEDO and know how the drug affects them. Concomitant use of alcohol or other sedating drugs may have additive effects and worsen sedation and somnolence.

Hyperprolactinemia: Tetrabenazine elevates serum prolactin concentrations in humans. If there is a clinical suspicion of symptomatic hyperprolactinemia, appropriate laboratory testing should be done and consideration should be given to discontinuation of AUSTEDO.

Binding to Melanin-Containing Tissues: Deutetrabenazine or its metabolites bind to melanin-containing tissues and could accumulate in these tissues over time. Prescribers should be aware of the possibility of long-term ophthalmologic effects.

CYP2D6 Metabolism: In patients who are poor CYP2D6 metabolizers or are taking strong CYP2D6 inhibitors, the total daily dosage of AUSTEDO should not exceed 36 mg (maximum single dose of 18 mg).

Common Adverse Reactions: The most common adverse reactions for AUSTEDO (>8% and greater than placebo) in a controlled clinical study in patients with Huntingtons disease were somnolence, diarrhea, dry mouth, and fatigue. The most common adverse reactions for AUSTEDO (4% and greater than placebo) in controlled clinical studies in patients with tardive dyskinesia were nasopharyngitis and insomnia.

Please see accompanying full Prescribing Information, including Boxed Warning.

About Teva

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve peoples lives for more than a century. We are a global leader in generic and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at http://www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding AJOVY and AUSTEDO, which are based on managements current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2019, including in the sections captioned "Risk Factors and Forward Looking Statements. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200501005015/en/

Original post:
New Data For Teva AJOVY (fremanezumab-vfrm) Injection and AUSTEDO (deutetrabenazine) Tablets Included in Neurology - BioSpace

Posted in Gene Medicine | Comments Off on New Data For Teva AJOVY (fremanezumab-vfrm) Injection and AUSTEDO (deutetrabenazine) Tablets Included in Neurology – BioSpace

Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes |…

Posted: at 3:52 pm

DetailsCategory: AntibodiesPublished on Friday, 01 May 2020 15:04Hits: 156

Recommendation for approval based on results from pivotal Phase 3 MEDALIST and BELIEVE studies

PRINCETON, NJ & CAMBRIDGE, MA, USA I April 30, 2020 IBristol Myers Squibb (NYSE: BMY) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Reblozyl (luspatercept) for the treatment of:

This CHMP recommendation will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU). If approved, Reblozyl would be the first erythroid maturation agent approved in the EU, representing a new class of therapy for eligible patients. The safety and efficacy results provided in the application are from the pivotal Phase 3 MEDALIST and BELIEVE studies, evaluating the ability of Reblozyl to effectively address anemia associated with MDS and beta thalassemia, respectively.

"Patients with myelodysplastic syndromes who experience anemia have limited treatment options, and some have been shown to not respond to available erythropoietin-based therapies," said Uwe Platzbecker, M.D., Head of Clinic and Policlinic for Hematology and Cell Therapy, Leipzig University Hospital and lead investigator of the MEDALIST study. If approved, the introduction of a new class of therapy in Reblozyl could provide a promising option to help relieve patients from the burden of regular transfusions to manage their disease.

Todays positive CHMP opinion of Reblozyl is an important milestone for adult beta thalassemia patients in the EU who have limited treatment options to address anemia, a serious consequence of the disease, said Maria Domenica Cappellini, M.D., Professor of Medicine, University of Milan, Fondazione IRCCS Ca Granda and lead investigator of the BELIEVE study. Reblozyl has the potential to significantly decrease the number of red blood cell transfusions patients need.

This decision by the CHMP is an important step towards making this first-in-class therapy an option for eligible patients with anemia due to beta thalassemia or myelodysplastic syndromes, said Diane McDowell, M.D., vice president, Hematology Global Medical Affairs, Bristol Myers Squibb. We, and our partners at Acceleron, look forward to the opportunity to make this treatment option available in the EU and are extremely appreciative of the patients, families and individuals who continue to help us progress important research in a range of serious diseases.

About MEDALIST

MEDALIST is a Phase 3, randomized, double-blind, placebo-controlled, multi-center study evaluating the safety and efficacy of luspatercept plus best supportive care (BSC) versus placebo plus BSC in adults with IPSS-R-defined very low-, low- or intermediate-risk non-del(5q) myelodysplastic syndromes (MDS). All patients were red blood cell (RBC) transfusion-dependent and were either refractory or intolerant to prior erythropoiesis stimulating agent (ESA) therapy, or were ESA nave and unlikely to respond due to endogenous serum erythropoietin levels of 200 U/L, and had no prior treatment with disease modifying agents. Results of the MEDALIST trial were first presented during the Plenary Session of the 2018 American Society of Hematology (ASH) Annual Meeting and were selected for the Best of ASH. The New England Journal of Medicine published the MEDALIST trial results in January 2020.

About MDS

MDS are a group of closely related blood cancers characterized by ineffective production of healthy red blood cells, white blood cells and platelets, which can lead to anemia and frequent or severe infections. People with MDS who develop anemia often require regular blood transfusions to increase the number of healthy red blood cells in circulation. Frequent transfusions are associated with an increased risk of iron overload, transfusion reactions and infections. There are approximately 50,000 patients with MDS in the EU5 countries.

About BELIEVE

BELIEVE is a Phase 3, randomized, double-blind, placebo-controlled multi-center study comparing luspatercept plus BSC versus placebo plus BSC in adults who require regular RBC transfusions (6-20 RBC units per 24 weeks with no transfusion-free period greater than 35 days during that period) due to beta thalassemia. Results of the BELIEVE trial were first presented at the 2018 ASH Annual Meeting and selected for the Best of ASH. The New England Journal of Medicine published the BELIEVE trial results in March 2020.

About Beta Thalassemia

Beta thalassemia is an inherited blood disorder caused by a genetic defect in hemoglobin. The disease is associated with ineffective erythropoiesis, which results in the production of fewer and less healthy RBCs, often leading to severe anemia a condition that can be debilitating and can lead to more severe complications for patients as well as other serious health issues. Treatment options for anemia associated with beta thalassemia are limited, consisting mainly of frequent RBC transfusions that have the potential to contribute to iron overload, which can cause serious complications such as organ damage. Across the United States, Germany, France, Italy, Spain and the United Kingdom, there are approximately 17,000 patients with beta thalassemia.

About Reblozyl

Reblozyl (luspatercept-aamt), a first-in-class erythroid maturation agent, promotes late-stage red blood cell maturation in animal models. Bristol Myers Squibb and Acceleron are jointly developing Reblozyl as part of a global collaboration. Reblozyl is currently approved in the U.S. for the treatment of:

Reblozyl is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.

Please see full Prescribing Information for REBLOZYL

Bristol Myers Squibb: Advancing Cancer Research

At Bristol Myers Squibb, patients are at the center of everything we do. The goal of our cancer research is to increase patients quality of life, long-term survival and make cure a possibility. We harness our deep scientific experience, cutting-edge technologies and discovery platforms to discover, develop and deliver novel treatments for patients.

Building upon our transformative work and legacy in hematology and Immuno-Oncology that has changed survival expectations for many cancers, our researchers are advancing a deep and diverse pipeline across multiple modalities. In the field of immune cell therapy, this includes registrational chimeric antigen receptor (CAR) T-cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. We are developing cancer treatments directed at key biological pathways using our protein homeostasis platform, a research capability that has been the basis of our approved therapies for multiple myeloma and several promising compounds in early to mid-stage development. Our scientists are targeting different immune system pathways to address interactions between tumors, the microenvironment and the immune system to further expand upon the progress we have made and help more patients respond to treatment. Combining these approaches is key to delivering new options for the treatment of cancer and addressing the growing issue of resistance to immunotherapy. We source innovation internally, and in collaboration with academia, government, advocacy groups and biotechnology companies, to help make the promise of transformational medicines a reality for patients.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook and Instagram.

Celgene and Juno Therapeutics are wholly owned subsidiaries of Bristol-Myers Squibb Company. In certain countries outside the U.S., due to local laws, Celgene and Juno Therapeutics are referred to as, Celgene, a Bristol-Myers Squibb Company and Juno Therapeutics, a Bristol-Myers Squibb Company.

About Acceleron

Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. The Company's leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.

Acceleron focuses its research and development efforts in hematologic and pulmonary diseases. In hematology, Acceleron and its global collaboration partner, Bristol Myers Squibb, are co-promoting REBLOZYL (luspatercept-aamt), the first and only approved erythroid maturation agent, in the United States and are developing luspatercept for the treatment of chronic anemia in myelofibrosis. Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension, having recently reported positive topline results of the Phase 2 PULSAR trial and actively enrolling patients in the Phase 2 SPECTRA trial.

For more information, please visit http://www.acceleronpharma.com. Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.

SOURCE: Bristol-Myers Squibb

Go here to read the rest:
Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes |...

Posted in Gene Medicine | Comments Off on Reblozyl (luspatercept) Receives Positive CHMP Opinion for the Treatment of Adults with Anemia in Beta Thalassemia and Myelodysplastic Syndromes |…

COVID-19 Retail Bankruptcies Ready to Boil Over – WWD

Posted: at 3:50 pm

The other shoe is about to drop.

A trio of high-profile, but struggling retailers including J. Crew Group, Neiman Marcus Group and J.C. Penney Co. Inc. are all said to be preparing to file for Chapter 11 bankruptcy protection by mid-May.

Together the three companies bring in sales of more than $18 billion annually and represent a wide swath of the industry from value-priced broadline retailing to mall-based specialty stores to refined department store luxury.

All of them have been on the industrys watch list for months, but each had plans to turn around their fortunes that appear to have been overwhelmed by the now six-week shutdown of the consumer economy that was forced by COVID-19.

J. Crew was betting on a spin-off and initial public offering for its successful Madewell division to satiate the companys debt holders. But the plan missed its window as markets tanked and multiple reports Thursday said a filing could come as soon as this week. A spokesman declined to comment.

Neiman Marcus missed an interest payment mid-month and has been on the cusp of filing for bankruptcy. It is reported to be working with multiple lender groups as it looks to secure the debtor-in-possession financing that would see it through Chapter 11.

J.C. Penney also missed an interest payment and has been exploring its options during a 30-day grace period. And while one source close to the situation said no decision has been made and that options other than bankruptcy remain on the table, another source familiar with the process said a filing could come May 14 or 15.

Even strong retailers tend to live hand-to-mouth, using their sales to cover their expenses and the industry has proven ill-equipped to handle a complete shutdown. It has responded by furloughing workers, canceling orders from suppliers and pushing off their landlords. Those actions have rippled up and down the supply chain, hurting companies of all kinds.

The question now for companies that came into the crisis in a heavily indebted or otherwise weakened position is: Even if they could survive through the immediate shutdown, would they be strong enough to survive the dire consumer landscape on the other side?

The U.S. economy was thrown into reverse in the first quarter, with gross domestic product falling 4.8 percent even though that included just a few weeks of real disruption in late March. The second-quarter contraction is expected to be one for the record books, topping 30 percent.

Thirty million people have applied for unemployment since the shutdown started and its not clear just when they will go back to work and start to spend.

Washington has raced to ease the pain and Federal Reserve chair Jerome Powell said this week the central bank would keep taking aggressive actions to support the economy.

The next phases are more uncertain, highly uncertain, but we will go through a phase starting fairly soon where we begin to reopen the economy, and probably the economic activity will pick up, as consumer spending picks up, Powell said. Consumer spending has gone down quite a lot. It will begin to pick up as people start to return to their normal patterns of spending.

Its a toxic brew that could lead to an especially harrowing trip through bankruptcy, which even in the best of times leads to cutbacks and store closings as the court tries to create a company that can stand on its own while often wiping out equity holders.

In todays climate its not clear just how long bankruptcy would last, whether landlords will be forced to essentially float rent payments for some time and stores destined to be closed for good could be liquidated.

J. Crew, J.C. Penney and Neiman Marcus are just the leading edge of what could be a massive wave of business failures. Ascena Retail Group Inc., Lord & Taylor and Academy also came into the crisis on debt watch lists.

And now, every retailer and brand is under the microscope, and their future prospects are being examined down to every last cent.

See the rest here:

COVID-19 Retail Bankruptcies Ready to Boil Over - WWD

Posted in Bankruptcy | Comments Off on COVID-19 Retail Bankruptcies Ready to Boil Over – WWD

COVID-19 pandemic likely put some bankruptcies on hold – ModernHealthcare.com

Posted: at 3:50 pm

COVID-19 will trigger a wave of healthcare bankruptcies in 2020, but the pandemic had the opposite effect in the first quarter.

That's because the economic turmoil in March likely threw a wrench in the exit strategies of companies that had previously planned to file last month. And since most of the damage hit in mid-March when many stay-at-home orders took effect, March 31 was too soon for most other filings.

"If there was no COVID, I think the number of bankruptcies would be a little higher," said Jeremy Johnson, a shareholder with the law firm Polsinelli who handles bankruptcies, said of the first quarter filings. "But then we know it's going to go up."

Polsinelli's first quarter 2020 distress report found the healthcare distress index grew by eight points in the recently ended quarter, which is 133% above the benchmark created in the fourth quarter of 2010. The report's distress index measures bankruptcy filings on a trailing, four-quarter basis, which the firm says smooths volatility and provides a better picture of long-term trends.

Polsinelli measured healthcare's distress index at 233.3 in the first quarter, significantly higher than the overall Chapter 11 distress index of 54.5, and the real estate distress index of 30.8.

The report includes all patient-facing healthcare, including hospitals, ambulatory surgery centers, physician clinics and behavioral health clinics. Lately, Johnson said it's been a lot of senior living facilities and hospitals. In the first quarter, that included Thomas Health in West Virginia and Randolph Health in North Carolina.

Although the bankruptcies that will inevitably be prompted by COVID-19 didn't hit in the first quarter, Johnson said they'll start to trickle in in the second, third and fourth quarters.

One example is for-profit Quorum Health Corp., whose hospitals are located in rural and mid-sized markets. The Brentwood, Tenn.-based company filed for Chapter 11 bankruptcy in early April, the second quarter. Quorum has lost money since its 2016 spinoff from Community Health Systems, and cited COVID-19 as one factor that prompted its filing.

Hospitals have been forced to halt profitable elective procedures during the pandemic, prompting steep revenue declines. That coupled with the expense of treating complex COVID-19 patients for extended periods of time has placed many in dire financial positions.

Most health systems have been scrambling to boost liquidity by drawing on credit lines, issuing bonds and taking out bank loans. But that won't be enough for some, especially smaller hospitals or health systems.

There's a legal question as to whether or not companies can file for bankruptcy while simultaneously collecting federal stimulus funding under the Coronavirus Aid, Relief, and Economic Security Act.

Cynthia Romano, a global director in CohnReznick's restructuring and dispute resolution practice, said companies are not allowed to collect stimulus relief while they're in bankruptcy, which will postpone healthcare filings to the third and fourth quarters "when stimulus funds are no longer in play."

Struggling healthcare providers could argue that's discrimination against companies that need stimulus funding the most, Johnson said. He predicts a forthcoming wave of litigation on that question. That may be a losing battle for providers, though, as the stimulus funding is likely to run out before their court victories, he said.

Lots of bankruptcies will correspond with lenders or private equity firms taking stock of their portfolios and determining where demand has rebounded and where it hasn't, Romano said.

"They will be making choices about who lives and who dies from a corporate perspective," she said.

In the first quarter, 71% of healthcare's Chapter 11 filings were among the smallest companies measured: those with $1 million to $10 million in assets, Polsinelli found. The report excludes companies with fewer than $1 million in assets. Johnson said it's typical for most bankruptcy filings to be smaller providers, especially rural hospitals.

The highest concentration of filings were in the Southeast, South and Pacific Northwest.

Healthcare bankruptcies had already been on the rise before the pandemic hit, Romano said. Healthcare comprised 2.9% of all corporate bankruptcies at the end of 2015 and 9.9% by the end of 2018, she said.

Now, in the age of COVID-19, even previously strong providers are on thin ice.

"I don't care how healthy you were," Romano said. "You think about the teetering ones, that puts them over the edge. If you think about the really healthy ones, that puts them in significant distress."

Excerpt from:

COVID-19 pandemic likely put some bankruptcies on hold - ModernHealthcare.com

Posted in Bankruptcy | Comments Off on COVID-19 pandemic likely put some bankruptcies on hold – ModernHealthcare.com

A Flood of Business Bankruptcies Likely in Coming Months – The New York Times

Posted: at 3:50 pm

NEW YORK The billions of dollars in coronavirus relief targeted at small businesses may not prevent many of them from ending up in bankruptcy court.

Business filings under Chapter 11 of the federal bankruptcy law rose sharply in March, and attorneys who work with struggling companies are seeing signs that more owners are contemplating the possibility of bankruptcy.

Companies forced to close or curtail business due to government attempts to stop the virus's spread have mounting debts and uncertain prospects for returning to normal operations. Even those owners receiving emergency loans and grants aren't sure that help will be enough.

The most vulnerable companies include the thousands of restaurants and retailers that shut down, many of them more than a month ago. Some restaurants have managed to bring in a bit of revenue by serving meals for takeout and delivery, but even they are struggling financially. Small and independent retailers, including those with online stores. are similarly at risk; clothing retailers have the added problem of winter inventory that they are unlikely to sell with spring here and summer approaching.

Independent oil companies whose revenue was slammed by the collapse in energy prices also are strapped, as are other companies that were already burdened with high debt levels before the virus struck.

Jennifer Bennett, who closed one of her San Francisco restaurants on Wednesday, was still waiting for the financial aid she sought from the federal, state and city governments. Even with the money, she doesnt know if the revenue will cover the bills when shes finally able to reopen Zazie especially if shes required to space tables six feet apart for social distancing.

Our occupancy is going to be cut 60% to 65%, Bennett says. I fear bankruptcy is a possibility.

Other small companies have similar anxieties, says Paul Singerman, a bankruptcy attorney with Berger Singerman in Miami.

There is no reliable visibility into when business operations will be able to resume the pre-COVID normal, Singerman says.

Even larger companies are in trouble, including already struggling retailers who had to shut their stores.

The jeans company True Religion filed for Chapter 11 earlier this month, saying extended closures of its stores in the pandemic have hurt its business. Recent reports say department store chains Neiman Marcus and J.C. Penney, which has struggled for years with slumping sales, could soon file for bankruptcy protection.

The number of Chapter 11 filings rose 18 percent in March from a year earlier, a dramatic swing from the 20 percent decrease in February, according to the American Bankruptcy Institute, a trade organization for attorneys and other professionals involved in bankruptcy proceedings. The numbers dont break out filings by company size, but given that the vast majority of companies are small to mid-size, it does give an indication that smaller companies are struggling.

The federal government has already approved or given out more than 2 million loans and grants to small businesses totaling nearly $360 billion; another $310 billion is on the way to one of the programs. Still, the money may be at best a stopgap for companies with little to no revenue coming in. And the new funds are expected to go so quickly that thousands of owners wont get loans.

Theres no way to predict how many companies will file for bankruptcy. There were over 160,000 bankruptcy filings from 2008 to 2010, during the Great Recession and its aftermath, according to statistics compiled by the federal court system. The numbers dont break out filings by company size. The majority were for liquidations. although some companies restructured their debt and continued operating under Chapter 11.

Many companies, however, just shut their doors, and thats likely to be the case again, Singerman says. According to some estimates, 170,000 companies failed during the recession.

But the Small Business Reorganization Act, which took effect in February, may encourage more companies to seek Chapter 11. The law is aimed at allowing owners to retain their ownership rather than lose their companies to their creditors; that is generally what happens in Chapter 11. The law also streamlines the reorganization process so a company is not wiped out by attorneys fees, says Edward Janger, a professor at Brooklyn Law School in New York whose expertise includes bankruptcy law.

Another change under the law is that a bankruptcy judge can approve the reorganization over creditors objections, Janger says.

Business owners will try to avoid bankruptcy by seeking leniency from landlords, lenders and vendors, bankruptcy attorney David Wander says. But with their companies financial troubles beyond their control because of the virus outbreak, many will file for Chapter 11 because the stigma that bankruptcy has long held will be gone, says Wander, a partner at Davidoff Hutcher & Citron in New York.

The tsunami is going to happen in the coming months and its going to be ongoing, Wander says.

Read the original here:

A Flood of Business Bankruptcies Likely in Coming Months - The New York Times

Posted in Bankruptcy | Comments Off on A Flood of Business Bankruptcies Likely in Coming Months – The New York Times

Suddenly, bankruptcy is on the mind of business owners – ThisisReno

Posted: at 3:50 pm

Feature Image: Trevor Bexon

Business owners in the Reno area arent rushing to file for bankruptcy protection, but theyre beginning to ask their lawyers about the possibilities.

Thats a good thing, the lawyers say. Too often in the past, business owners have waited until theyve watched all their assets personal, sometimes, along with the business dwindle away before they seek the shelter of bankruptcy.

Plus, it reduces the worry.

The unknown is what is so scary for a lot of people, says Tricia Darby, who practices bankruptcy law in Reno with her husband, Kevin. Were visiting today with smart people who want to understand what their options might be.

Timothy Lukas, who specializes in bankruptcy as a partner at the law firm of Holland & Hart in Reno, says unknowns abound for business owners as a result of the freeze-in-place orders by state and local officials six weeks ago.

There are still a lot of unknowns about when and how our local economy will emerge from the current financial crisis, says Lukas. The abrupt, system-wide disruption to the economy means business owners and lenders need to work out the problems theyre facing.

The federal stimulus packages designed to help business weather the COVID-19 storm present even more issues to sort through.

The current stimulus bills prohibit or limit relief if a business chooses to file for bankruptcy.Right now, all of the obligations and commitments for business owners remain in place, Lukas says.

On the other hand, Darby says Congress opened the doors for more small businesses that are floundering as a result of the pandemic to reorganize under the protection of Chapter 11 bankruptcy protection. Some filing deadlines were extended.

But Lukas cautions that those measures are valid only for a year.

If one waits too long to file for bankruptcy, it can be a disaster, he says, recommending that business owners and their attorneys understand today what a bankruptcy filing could accomplish or not if theres even a chance that a company will go under.

Chapter 11 bankruptcy filings cases in which businesses try to regroup while they get their feet back underneath themselves were declining in the region before the pandemic-related shutdowns. Last year saw 14 filings of Chapter 11 cases in U.S. Bankruptcy Court in Reno. That compared with 26 a year earlier.

Chapter 7 cases the ones in which a judge oversees the liquidation of a business totaled 566 last year. A year earlier, 1,133 of those cases were filed in the bankruptcy court in Reno.

A note from our publisher

This Is Reno, like most other news outlets, has been hit incredibly hard by COVID-19. We have cut back on some important news coverage; however, we are continuing to provide daily news on COVID-19s impacts on the Reno area. These articles are provided free of charge and outside of our paywall. If you can help, any amount is appreciated whether a donation, subscription or advertising your business with This Is Reno.

Criticism against Governor Steve Sisolak is ramping up after he surprised Nevadans with plans to reopen the state on national media.

OPINION: With such an abundance of health and nutrition information, how do you separate fact from fiction? UNRs Extension provides tips to sort through the junk science.

There was another death announced today from the coronavirus disease. County officials reported a man in his 70s with underlying health conditions died. He is the 30th

A group of local business leaders launched Hospitality Industry Partnerships, HIP, to help feed out of work restaurant, bar and gaming employees.

OPINION: Berkbigler, a lobbyist and politician by trade, is showing she believes she knows more about science than medical specialists, epidemiologists and public health experts.

Business owners in the Reno area arent rushing to file for bankruptcy protection, but theyre beginning to ask their lawyers about the possibilities.

Learn more about COVID-19, its origins, how it spreads, and why scientists and healthcare providers say it is far more worrisome than the flu.

OPINION: At a time in history when positive news is hard to come by, Renos citizens should be proud that our Specialty Court system is both resilient

Governor Steve Sisolak announced Monday Nevada would be joining the Western States Pact, a group of state governors working together on a coordinated plan to manage the

This Is Reno was contacted by readers who were concerned and dismayed upon seeing photographs of officers shaking hands and without masks.

Continued here:

Suddenly, bankruptcy is on the mind of business owners - ThisisReno

Posted in Bankruptcy | Comments Off on Suddenly, bankruptcy is on the mind of business owners – ThisisReno

Can states file for bankruptcy? Should they? What you need to know – PolitiFact

Posted: at 3:50 pm

As states struggle under the weight of the coronavirus pandemic, Congress and the president have enacted a series of massive bills to try to bolster the health care response and help rescue the economy.

But Senate Majority Leader Mitch McConnell, R-Ky., recently made a comment that suggests hes tired of big spending for cash-strapped states.

The National Governors Association has asked Congress for $500 billion more in direct federal aid, on top of the $150 billion provided in the $2.2 trillion coronavirus relief bill that passed in recent weeks. Depending on how long the crisis lasts, that number could go higher.

McConnell said in a radio interview that states might be better off declaring bankruptcy than by expecting additional funding from the federal government.

"I would certainly be in favor of allowing states to use the bankruptcy route. It saves some cities. And theres no good reason for it not to be available," McConnell said. "My guess is their first choice would be for the federal government to borrow money from future generations to send it down to them now so they dont have to do that. Thats not something Im going to be in favor of."

Bankruptcy gives a "fresh start" to debtors who are unable to satisfy their debts. Declaring bankruptcy may involve a restructured payment schedule for obligations, such as pension debt or interest payments on bonds, as well as relief from bills from vendors. The parties may negotiate over the terms, overseen by specialized bankruptcy courts.

For states, bankruptcy would be a novel approach, since it doesnt currently exist under law. And given the unusual confluence of urgent congressional business, along with the difficulties of carrying out ordinary legislative activities in an era of social distancing, experts do not expect state bankruptcy to become a reality in the immediate future.

McConnells comments prompted widespread criticism, including from some Republicans.

Maryland Republican Gov. Larry Hogan, said, "Mitch McConnell, I think, probably regrets saying that. If he doesn't regret it yet, I think he will regret it. The last thing we need in the middle of an economic crisis is to have states filing bankruptcy all across America and not able to provide services to people who desperately need them."

Rep. Pete King, R-N.Y., called McConnells comment "shameful and indefensible," while New Yorks Democratic governor, Andrew Cuomo, called it "one of the really dumb ideas of all time."

So whats the hubbub all about? Lets take a closer look.

Currently, can states declare bankruptcy?

Its important to note that, under current law, states cannot declare bankruptcy. So Congress would need to pass a law allowing it.

The primary reason for the lack of state bankruptcy provisions is the U.S. Constitution. "Under the Constitution, states are sovereign entities, and the federal government has limited power to act on them directly," said Vincent Buccola, an assistant professor of legal studies and business ethics at the University of Pennsylvanias Wharton School.

In an analysis, Kenneth Katkin, a law professor by Northern Kentucky University, wrote that "the contracts clause of the Constitution prohibits state governments from impairing the obligation of contracts. As originally understood and enforced, this clause prohibited state legislatures from passing any laws to relieve either private debt or the state government's own debt."

While the Supreme Courts interpretation of bankruptcy law has varied during the 20th century, state bankruptcy was never seen as a permissible option. Even if a law did pass, David Schleicher, a professor at Yale Law School, told us there would be constitutional challenges.

Is there historical precedent for state bankruptcy being on the table?

While there is no historical precedent for states having access to bankruptcy, "there are many historical instances of states defaulting on their debts," Schleicher told PolitiFact.

In the 1840s, eight states and one territory defaulted on their debt; for some, payments resumed quickly, while others renounced their debt and never paid. In the 1870s, he said, most southern states renounced their Reconstruction-era debt, and in 1933, Arkansas defaulted on its debt.

Most recently, there was discussion of allowing state bankruptcies in the wake of the Great Recession. The U.S. House even held a hearing on the idea.

However, the concept drew fire from Wall Street, public-employee unions, and governors from both parties, who worried about the risk of rising interest rates, Bloomberg reported. Nothing was enacted.

Matt Fabian, a partner with Municipal Market Analytics, told Bloomberg that todays discussion of state bankruptcy is "just a red herring. State bankruptcy is probably not possible under the U.S. Constitution, and theres even less chance that Congress would attempt to allow it."

Are cities treated differently when it comes to the bankruptcy option?

Unlike states, cities are able to declare bankruptcy under Chapter 9 of the bankruptcy code. That chapter allows for the reorganization of municipalities, which include cities, towns, villages, counties, taxing districts, municipal utilities, and school districts.

"Municipalities, which are created by states, can use Chapter 9 as part of the bankruptcy law designed specifically for governmental organizations," even though states cannot use it, Buccola said. To avail itself of bankruptcy, the municipality must be authorized by its state.

The Great Depression in the 1930s saw a spike in municipal defaults, but they became less common in subsequent decades. Many of those that did occur stemmed from small local governments facing a giant debt due to embezzlement or a sizable legal judgment, Schleicher said.

New York City managed to avoid bankruptcy in the 1970s thanks to negotiations between the state, investors, and labor unions. There has been another uptick of municipal bankruptcies since the Great Recession, including Jefferson County, Ala., Stockton, Calif., and Detroit.

What would "bankruptcy" look like for a state?

Buccola said that a state bankruptcy provision would likely look more like chapter 9 for municipalities than either chapter 11, which is used by businesses, or chapter 7, which is used by individuals.

Under such a system, "the state alone could propose adjustments to its debts, and it would be up to a federal judge to determine whether the package of adjustments a debtor state proposes meet the requirements of the law," Buccola said.

Samir Parikh, a law professor and co-director of the Center for Business Law and Innovation at Lewis & Clark Law School, said the states current fiscal challenges stem not just from the unusual circumstances of the coronavirus pandemic, but also from past decisions on matters such as pensions for retired state workers.

States "need to find a way to address their pension underfunding," Parikh said. "Concessions from labor unions represent the best bet. Many state constitutions prohibit states and municipalities from unilaterally altering pension and health care benefits. Municipal bondholders are the other group that would need to take a haircut."

He said that in Detroits now-ended bankruptcy, for instance, judges were asked to serve as arbitrators to negotiate with unions and bondholders with an eye toward a consensus settlement. "The parties were incentivized because they were worried about the debtor having the power to unilaterally alter payments and benefits."

Why are states wary of allowing bankruptcy?

For a state, declaring bankruptcy could have negative consequences on the future perceptions of their creditworthiness.

"States and municipalities are hesitant because they could get locked out of credit markets, and those funds are necessary to fill large gaps in budgets," Parikh said.

In addition, potential vendors might decline opportunities to work with the state, for fear that they wouldnt get paid the agreed-upon amounts. And state officials might have to contemplate selling off state assets, such as park lands, to raise money.

What are the alternatives to bankruptcy?

The main alternative to state bankruptcy is the one McConnell was reacting against increased federal financial support for states, which ultimately must come either from taxpayers or from issuing additional debt.

Another possibility would be a hybrid model that includes higher federal aid along with a bankruptcy system for the most difficult cases, such as states that have had longstanding pension imbalances.

Original post:

Can states file for bankruptcy? Should they? What you need to know - PolitiFact

Posted in Bankruptcy | Comments Off on Can states file for bankruptcy? Should they? What you need to know – PolitiFact

State bankruptcy is irrelevant to COVID-19 and bailouts aren’t the answer | TheHill – The Hill

Posted: at 3:50 pm

The nations governors have asked for at least $500 billion in federal bailouts to make up for falling state revenues and to backfill their systemically underfunded pension plans. Some members of Congress have seconded the request, but, Senate Majority Leader Mitch McConnellAddison (Mitch) Mitchell McConnellCapitol physician doesn't have enough coronavirus tests for all lawmakers as Senate plans return Overnight Health Care: Pelosi floats almost T for states | US intel investigating COVID-19's origins | Trump outlines efforts to protect nursing homes The Hill's Campaign Report: Pressure grows on Biden to address Tara Reade allegations MORE (R-Ky.) recently suggested that states have another option: Bankruptcy.

The fact is, no state or local government will need to declare bankruptcy just because of COVID-19. Rather, if states or municipalities do face insolvency, it will be the result of decades of fiscal mismanagement.

The important takeaway behind Sen. McConnells statement is that the federal government is not responsible for states budgets.

Yes, the federal government has an obligation to help cover the costs of addressing the pandemic. To that end, Congress has already sent states unprecedented aid.

And, yes, state and local governments are experiencing a decline in income-, sales-, and some other tax revenues. But unforeseen circumstances is one of the reasons states have rainy day funds. In aggregate, those funds were at an all-time-high prior to COVID-19, but not every state was well-prepared. While Wyoming had an entire years worth of revenue saved away, Illinois and Kansas had mere minutes of revenue saved.

COVID-19 could be the straw that broke the camels back for states already headed toward insolvency. But it alone isnt sufficient to create a need for either bailouts or bankruptcy.

When Puerto Rico entered bankruptcy, its debt equaled about three times its annual revenues. And when Detroit entered bankruptcy in 2013, the citys debt was 13 times its annual revenues. A few months or even a few years of lower revenues wont create bankruptcy situations for states. Government insolvency results from prolonged, systemic mismanagement.

Already, the federal government has provided state and local governments with direct grants worth $150 billion to help cover COVID-19 expenses. And it appears that states dont need more money for that. Otherwise, why have governors asked for flexibility to use these funds for non-pandemic costs? Why have some used the money for temporarypay raisesandbonusesfor public-sector workers, while26 million Americans have lost their paychecks?

Then theres the Federal Reserves $500 billion in unprecedented short-term lending to state and local governments. That amounts to half of every state and local governments annual income- and sales-tax revenues. Its unlikely those revenues will fall by 50 percent, if only because Congress has provided roughly $1.3 trillion in the form of small-business grants and loans, checks to households and massively-expanded unemployment insurance benefits all of which will help prop up state and local tax receipts.

Its becoming increasingly clear that what states really want is just an all-purpose bailout for their pre-existing problems.

Prior to the pandemic and despite the exceptionally strong economy, New York Gov. Andrew CuomoAndrew CuomoNewsom signs order allowing couples to obtain marriage licenses via videoconference Connecticut governor unveils four-stage plan to reopen state's economy Overnight Defense: Sexual assaults increase across military | Army defends bringing cadets back for Trump graduation speech MORE was facing a $6.1 billion annual budget deficit. Illinois had projected a $3.2 billion deficit.

The $40 billion in federal taxpayer funds requested by Illinois Senate Democratic Caucus would go mostly to financing the states consciously-enacted deficit and propping up its bloated pension systems, which entered the year with an unfunded liability of $137 billion.

If Congress were to provide a nation-wide state bailout proportionate to what Illinois requested, it would cost federal taxpayers an additional $1 trillion. Thats not far off from what House Speaker Nancy PelosiNancy PelosiMcCarthy doubtful Republicans will participate in coronavirus select committee Overnight Health Care: Pelosi floats almost T for states | US intel investigating COVID-19's origins | Trump outlines efforts to protect nursing homes On The Money: 3.8M more Americans file for unemployment benefits | Stocks cap off best month since 1987 even as coronavirus leaves millions jobless | Pelosi floats almost T for states in next relief package MORE (D-Calif.) is seeking.

Theres a fundamental unfairness to state bailouts. They force taxpayers in well-run states to subsidize those who have systematically squandered a strong economy and shortchanged pension plans of trillions of dollars worth of required contributions.

Some have suggested requiring more prudent budgeting from states that accept bailouts. Its a rather ironic suggestion, considering that the federal governments fiscal recklessness has created over $70,000 in debt per capita, while state debt averages less than $10,000 per capita.

Moreover, bailing out states denies the problems of socializing costs. If youve ever gone out to dinner with a large group, you might remember how the expensive steak, an extra drink and dessert are more appealing if those costs are split by everyone at the table. If thats what everyone is thinking, then everyone pays more in the end.

Socializing government debts by redistributing state and local costs to federal taxpayers in times of crisis is like splitting the check: Everyone still pays they just wind up paying a lot more.

Rachel Greszler is a research fellow in The Heritage Foundations Center for the Federal Budget. Adam N. Michel is a senior policy analyst in the center.

Read this article:

State bankruptcy is irrelevant to COVID-19 and bailouts aren't the answer | TheHill - The Hill

Posted in Bankruptcy | Comments Off on State bankruptcy is irrelevant to COVID-19 and bailouts aren’t the answer | TheHill – The Hill

Omdahl: Is state bankruptcy on the horizon? – INFORUM

Posted: at 3:50 pm

According to the National Conference of State Legislatures, 15 states have identified new holes in their budgets which by state constitutional provisions must be balanced.

Moodys Analytics predicts that our shrinking economy could result in state revenue drops of 18 to 23 percent.

North Dakota payrolls have been cut; Main Street has been closed; tax collections have nose-dived and manufacturing curtailed. While the North Dakota Legacy Fund, now bulging with over $6 billion, may look like a solution, raiding the fund would require an impossible two-thirds vote in both houses of the legislature.

RELATED

Even in the face of tremendous needs in states rising out of the coronavirus, McConnell alleges that states should solve the problem themselves without getting bailout money from the federal government.

Fund Restrictions

States have been bastions of frugality, saddled with scores of restrictions on taxing and spending accumulated through the years. Most states have constitutional or statutory restrictions that reduce their ability to respond to a sudden crisis.

Almost half of the states have provisions for proposing and amending statutes by citizen petition. Under these provisions, citizens can impose restrictions, thereby reducing options at the state level. North Dakota citizens have the initiative and referendum as well as the power to amend the state constitution.

Poverty Budgets

Because of all of these fiscal controls, governors and legislatures have kept their budgets on the edge of poverty. Even North Dakota policymakers will look at the $6 billion Legacy Fund while claiming poverty.

In addition to the virus pandemic, North Dakota is experiencing a collapse of the oil industry, which is no small matter in a state that ranks second to only Texas in oil production.

Associated Press Writer James McPherson reports that the legislature estimated oil at $48 per barrel for the present biennium. The market has been as low as $10 and $25.

Big oil Losses

According to McPhersons report, Tax Commissioner Ryan Rauschenberger estimates that price and production cuts could cost the state $288,000 in daily tax revenue.

There is little doubt that the legislature will be making draconian cuts in the state budget when it meets in Bismarck this winter. Basic government services will be funded, but social service, health programs and education will be on the chopping block.

For years North Dakota has had some citizens who favor reducing the number of universities and colleges in the state higher education system. In the anticipated budget crunch, the smaller colleges will not escape changes.

Some will propose closing Mayville, Bottineau, Williston and Devils Lake for starters. If not closing, a strict realignment of programming will alter the missions of various institutions.

With every state program in jeopardy, it would be wise to invest your government stimulus check in Bismarck hotels for the session. They should be very profitable.

North Dakota wont go bankrupt but it will go frugal. More than usual, that is.

Read the original:

Omdahl: Is state bankruptcy on the horizon? - INFORUM

Posted in Bankruptcy | Comments Off on Omdahl: Is state bankruptcy on the horizon? – INFORUM